Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
K. Kostikas (Ioannina, Greece), E. Loefroth (Kista, Sweden), I. Kottakis (Basel, Switzerland), P. Mcgettigan (Dublin, Ireland), M. Mcsharry (Dublin, Ireland), H. Cao (East Hanover, United States of America). Late Breaking Abstract - Difference in clinical outcomes between smoking and non-smoking asthma patients who initiated an ICS or ICS/LABA treatment. 3711

Member's Comments

No comment yet.

Related content which might interest you: Late Breaking Abstract: Fluticasone/salmeterol combination confers significant benefits in smoking asthmatics Source: Annual Congress 2010 - Smoking related diseases, damages due to environmental tobacco smoke and smoking control strategies Year: 2010 Late Breaking Abstract - Short-term and maintenance oral corticosteroid use for German patients with asthma Source: International Congress 2019 – Powerful cohort studies with/without lung function Year: 2019 Late Breaking Abstract - Cost effectiveness of as-needed budesonide/formoterol vs low-dose ICS maintenance therapy in mild asthma patients: A UK perspective Source: International Congress 2019 – How to guide patients to reach a balance between costs and personal needs: quality indicators of effectiveness Year: 2019 Late Breaking Abstract - Impact of maintenance and reliever therapy (MART)-focused asthma guideline on SABA prescriptions Source: Virtual Congress 2021 – Highlights for primary care in 2021 Year: 2021 CAPTAIN: Effects of smoking status on response to triple therapy in patients with inadequately controlled asthma on ICS/LABA Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights Year: 2020 Influence of patient baseline characteristics and concomitant medication on outcomes in long-term trials of COPD: Analysis of the UPLIFT® trial Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 Effect of QVA149 on lung function in the subgroup of patients with a history of exacerbations in the previous year and baseline ICS use from the SHINE study Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Late Breaking Abstract - Real-world evidence of dual bronchodilator therapy using Clinical COPD Questionnaire in 4700 COPD patients Source: Virtual Congress 2020 – Advances in pharmacological treatment of COPD Year: 2020 Late Breaking Abstract - Impact of ICS/LABA and LABA/LAMA FDCs on lung function and exacerbation of COPD: a network meta-analysis Source: International Congress 2018 – Pharmacological management of COPD Year: 2018 Late Breaking Abstract - A randomized clinical study to assess the impact of budesonide/formoterol (BUD/FM) pMDI medication reminders on adherence in COPD patients Source: International Congress 2018 – Integrating pharmacological and non-pharmacological management in COPD: are we there yet? Year: 2018 Late Breaking Abstract - The burden of intermittent oral corticosteroid use in asthma Source: Virtual Congress 2021 – Asthma treatment: clinical and translational science Year: 2021 Difference between asthma and COPD patients in adherence and non-adherence patterns to inhaler devices Source: International Congress 2015 – Is asthma always an easy disease to diagnose and manage? Year: 2015 Maintenance and reliever combination budesonide/formoterol therapy in asthma patients at risk of severe exacerbations: A randomised controlled trial Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD Year: 2013 1-year efficacy and safety study of tiotropium respimat add-on to ICS in adolescent patients with symptomatic asthma Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 Clinical predictors of the effectiveness of tiotropium in adults with symptomatic asthma: the real-life data Source: International Congress 2018 – Tests and trends in asthma Year: 2018 Impact of adherence to fluticasone propionate/salmeterol combination (FSC) therapy on the outcomes of patients with asthma: A population based study Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease Year: 2013 Late Breaking Abstract - Effect of inhaled corticosteroids on exacerbation of asthma–COPD overlap according to different diagnostic criteria Source: International Congress 2019 – COPD clinical studies: bronchodilators, corticosteroids and more Year: 2019 Real-life asthma impairment: SABA use depends on smoking phenotype Source: Annual Congress 2013 –Treatment and management of asthma in primary care Year: 2013 Late Breaking Abstract - Influence of salbutamol use on symptomatic outcomes with maintenance bronchodilators: a pre-specified analysis of the EMAX trial Source: International Congress 2019 – New towards old therapies in airway diseases Year: 2019 Fracture rate in patients with asthma receiving long-term early intervention with budesonide: the START study Source: Eur Respir J 2005; 26: Suppl. 49, 276s Year: 2005